Navin Verma, MD
Nephrology · Hershey, PANPI 1346299625
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,784 of the $6,954 with a category attached, or 83.2%. Travere Therapeutics, Inc. accounts for 62.3% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $6,577, more than ten times the $79 reported in 2019. Among nephrology clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 26 payments — averaging $267.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Travere Therapeutics, Inc.$4K
- Calliditas Therapeutics US Inc.$2K
- EMD Serono, Inc.$103
- Baxter Healthcare$93
- Aurinia Pharma U.S., Inc.$93
- Novartis$88
- plus $60 from 2 others
What the payments were for
- Consulting fees$5,78483%
- Travel & lodging$4016%
- Food & beverage$76911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Travere Therapeutics, Inc. | 9 | $4,333 |
| Calliditas Therapeutics US Inc. | 1 | $2,184 |
| EMD Serono, Inc. | 7 | $103 |
| Baxter Healthcare | 2 | $93 |
| Aurinia Pharma U.S., Inc. | 1 | $93 |
| Novartis | 4 | $88 |
| Vertex | 1 | $35 |
| Biogen | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,954 in reported general payments places this provider in the 90th percentile of 586 nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 20 | $21,311 |
| Sevelamer Carbonate | 99 | $18,180 |
| VeltassaPatiromer Calcium Sorbitex | 16 | $17,346 |
| FarxigaDapagliflozin Propanediol | 11 | $17,174 |
| LokelmaSodium Zirconium Cyclosilicate | 27 | $14,622 |
| Sevelamer Hcl | 13 | $14,045 |
| Cinacalcet Hcl | 17 | $11,403 |
| Clonidine | 17 | $3,224 |
| Bumetanide | 37 | $2,289 |
| Calcitriol | 139 | $1,878 |
| Losartan Potassium | 127 | $1,618 |
| Lisinopril | 174 | $1,345 |
| Gentamicin Sulfate | 27 | $973 |
| Carvedilol | 58 | $884 |
| Amlodipine Besylate | 128 | $792 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Hershey
- Umar FarooqHershey$100K
- Nelson KopytAllentown$949K
- Christopher GislerPittsburgh$757K
- Rakesh GulatiPhiladelphia$657K
- Raymond TownsendPhiladelphia$357K
- Prince AnandDanville$331K
- Ellie KelepourisPhiladelphia$287K
- Jonathan DiamondHarrisburg$249K
- Abdallahsassine GearaPhiladelphia$225K
- Khaled NasharPittsburgh$198K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.